Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against INSYS Therapeutics, Inc. (“INSYS” or the “Company”) (Nasdaq: INSY). Investors who purchased or otherwise acquired shares between March 3, 2015 and January 25, 2016, inclusive (the “Class Period”) are encouraged to contact the Firm prior to the April 4, 2016 lead plaintiff motion deadline.

If you purchased shares of INSYS during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (i) the Company was engaged in the illegal and improper off-labeling marketing of Subsys; (ii) certain INSYS employees—including Defendant Michael L. Babich, the President and Chief Executive Officer of INSYS during much of the Class Period—were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (iii) as a result, the Company’s financial statements were materially false and misleading at all relevant times.

If you purchased shares of INSYS during the Class Period, you have until April 4, 2016 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.